Research programme: liver fibrosis therapy - Metabasis Therapeutics
Alternative Names: Liver fibrosis therapy research programme - Metabasis Therapeutics; MB 07100Latest Information Update: 25 Apr 2007
At a glance
- Originator Metabasis Therapeutics
- Class
- Mechanism of Action Purinergic P1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatic fibrosis
Most Recent Events
- 25 Apr 2007 Discontinued - Preclinical for Hepatic fibrosis in USA (unspecified route)
- 24 Aug 2005 This compound is still in active development
- 01 Apr 2004 Metabasis Therapeutics has selected MB 07100 as the lead compound from this research program